http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 20 May 2026 17:29:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++PURPLE+BIOTECH+LTD.++++++++++++++++++/26529631.html si-local-file:///var/storage/secattach/20260520/26529631.html http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++PURPLE+BIOTECH+LTD.++++++++++++++++++/26529631.html Wed, 20 May 2026 17:29:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++PURPLE+BIOTECH+LTD.++++++++++++++++++/26529631.html si-local-file:///var/storage/secattach/20260520/26529631.html http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++PURPLE+BIOTECH+LTD.++++++++++++++++++/26529631.html Wed, 20 May 2026 17:29:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++PURPLE+BIOTECH+LTD.++++++++++++++++++/26529631.html si-local-file:///var/storage/secattach/20260520/26529631.html http://www.streetinsider.com/SEC+Filings/Form++F-3++++++++PURPLE+BIOTECH+LTD.++++++++++++++++++/26529631.html Wed, 20 May 2026 17:29:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+May+15/26499220.html si-local-file:///var/storage/secattach/20260515/26499220.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+May+15/26499220.html Fri, 15 May 2026 07:02:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+May+15/26499220.html si-local-file:///var/storage/secattach/20260515/26499220.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+May+15/26499220.html Fri, 15 May 2026 07:02:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+May+15/26499220.html si-local-file:///var/storage/secattach/20260515/26499220.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+May+15/26499220.html Fri, 15 May 2026 07:02:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html <p align="center"><em>New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples</em></p> <p align="center"><em>Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational oncology</em></p> <p align="center"><em>Expanded collaboration with Converge Bio to apply generative AI to accelerate the design and optimization of next-generation tri-specific antibodies</em></p> <p align="center"><em>Total Cash Position of $6.4 million as of March 31, 2026, expected to provide runway into 2027 based on current management estimates</em></p> <p align="justify">REHOVOT, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Globe+Newswire/Purple+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Business+Highlights/26499111.html Fri, 15 May 2026 07:00:00 -0400 A.06822034 A.23636062 O.07128796 O.20026344 O.41740509 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26486588.html si-local-file:///var/storage/secattach/20260513/26486588.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26486588.html Wed, 13 May 2026 16:26:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26486588.html si-local-file:///var/storage/secattach/20260513/26486588.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26486588.html Wed, 13 May 2026 16:26:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26486588.html si-local-file:///var/storage/secattach/20260513/26486588.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PURPLE+BIOTECH+LTD.++++++++++++++++++++Filed+by%3A+INTRACOASTAL+CAPITAL%2C+LLC/26486588.html Wed, 13 May 2026 16:26:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Apr+27/26369722.html si-local-file:///var/storage/secattach/20260427/26369722.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Apr+27/26369722.html Mon, 27 Apr 2026 07:15:00 -0400 O.07128796 PPBT PPBT http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Apr+27/26369722.html si-local-file:///var/storage/secattach/20260427/26369722.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PURPLE+BIOTECH+LTD.+++++++For%3A+Apr+27/26369722.html Mon, 27 Apr 2026 07:15:00 -0400 O.07128796 PPBT PPBT